September 23rd, 2020 at the following times:
6:00PM - 9:30PM Central European Time
12:00PM - 3:30PM Eastern Time

Implandata Ophthalmic Products GmbH

Implandata is going to transform glaucoma care via its disruptive EYEMATE system for continual measurement and remote monitoring of intraocular pressure. EYEMATE is providing currently unobtainable real life information about glaucoma patients response to pressure lowering therapies, enabling proactive and personalized glaucoma treatment. Patient self-measurement of intraocular pressure empowers patients and improves their therapy adherence.

Implandata obtained CE mark for its system and is currently launching the product in Europe and other market, accepting CE mark. The EYEMATE consists of an implantable permanent microsensor for telemetric measurement of intraocular pressure. Data is acquired under normal life conditions at the patients home and transferred into a cloud-based medical database, making data available to eye doctors and patients.


Keranova is a dynamic start up company focused on the next generation in anterior segment surgery by developing new technologies and approaches in order to bring surgeons the laser system of the future. Using novel wavefront modification of the laser beam to create multiple spots and proprietary energy threshold mapping of the lens, Keranova can photoemulsify dense cataracts for aspiration without phaco energy. A robotic docking arm enables automated assistance of the docking procedure, and allows the entire arm to be moved out of the surgical field. Designed to be mobile and built for the operating room, the Keranova system integrates the laser, fluidics, and phaco elements into one package. The advanced optical system also delivers excellent cornea incisions and lasik flaps.


Oculis is a clinical stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases for both back- and front-of-the-eye in order to improve the sight and the lives of patients worldwide.


Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing treatments to preserve vision in patients with diseases affecting the back of the eye. The company has built a diverse portfolio of disease-modifying therapies, including treatments for diabetic eye disease, a leading cause of blindness in people of working age worldwide. Headquartered in Leuven, Belgium, Oxurion is listed on the Euronext Brussels exchange under the symbol OXUR. In the US, Oxurion NV operates ThromboGenics inc. as a subsidiary company.

Resono Ophthalmic

Resono Ophthalmic was created in Italy in 2014 after several years of scientific research and prototype development. Its mission is the development and commercialisation of highly innovative therapeutic devices for ophthalmology. The key feature is the exploitation of Quantum Molecular Resonance (QMR®), a patented technique capable of stimulating the natural cellular and tissue regeneration via low-power high-frequency electric fields.The first ophthalmic application of QMR® is the treatment of the dry eye disease (DED) and other ocular surface disorders with the Rexon-Eye®, a medical device covered by several international patents that obtained the EC certification and introduced to the market in 2018. Clinical trials in Italy and abroad, already completed or in progress, have clearly demonstrated that Rexon-Eye® is a safe and effective treatment option to improve subjective and objective symptoms in DED, both evaporative as well as aqueous deficient type. Rexon-Eye® is currently distributed worldwide in more than 15 countries.


Voptica is an innovative pioneer, discovering new frontiers in the field of Personalized Vision Testing and Correction (PVT&C). By bringing to market VAO, the company's unique instrument that provides patient and practitioner a reliable pre-surgical visualization of post-surgical vision, together with ArtIOL, an equally unique suite of meniscus-shaped EDOF IOLS, VOPTICA is opening a new era of personalized ophthalmic surgical outcomes.

The combined use of VAO (to facilitate ideal IOL selection), together with the smart visual optics technology of ArtIOL lenses, provides an unprecedented value proposition to the promising market of personalized care in the Ophthalmic space.

As VAO and ArtIOL come to market, VOPTICA continues to develop a remarkable pipeline of projects that will further enhance and consolidate the company's pioneering role in PVT&C.